BR112016023839A8 - Complexo de tanato de sitagliptina, composição farmacêutica, intermediário farmacêutico, forma de dosagem oral, e, uso de um complexo de tanato de sitagliptina - Google Patents
Complexo de tanato de sitagliptina, composição farmacêutica, intermediário farmacêutico, forma de dosagem oral, e, uso de um complexo de tanato de sitagliptinaInfo
- Publication number
- BR112016023839A8 BR112016023839A8 BR112016023839A BR112016023839A BR112016023839A8 BR 112016023839 A8 BR112016023839 A8 BR 112016023839A8 BR 112016023839 A BR112016023839 A BR 112016023839A BR 112016023839 A BR112016023839 A BR 112016023839A BR 112016023839 A8 BR112016023839 A8 BR 112016023839A8
- Authority
- BR
- Brazil
- Prior art keywords
- complex
- sitagliptin
- thannate
- pharmaceutical
- dosage form
- Prior art date
Links
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 title abstract 7
- 229960004034 sitagliptin Drugs 0.000 title abstract 7
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 239000006186 oral dosage form Substances 0.000 title abstract 2
- 239000012450 pharmaceutical intermediate Substances 0.000 title abstract 2
- 229920002253 Tannate Polymers 0.000 abstract 3
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
COMPLEXO DE TANATO DE SITAGLIPTINA, COMPOSIÇÃO FARMACÊUTICA, INTERMEDIÁRIO FARMACÊUTICO, FORMA DE DOSAGEM ORAL, E, USO DE UM COMPLEXO DE TANATO DE SITAGLIPTINA. A presente invenção refere-se a um complexo de tanato de sitagliptina ou a composições farmacêuticas ou intermediários farmaceuticamente aceitáveis compreendendo o referido complexo. Esta invenção também se refere aos processos para preparar o complexo de tanato de sitagliptina, bem como aos métodos para usar o complexo de tanato de sitagliptina para tratar diabetes, obesidade e hipertensão.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461980641P | 2014-04-17 | 2014-04-17 | |
PCT/US2015/025504 WO2015160678A1 (en) | 2014-04-17 | 2015-04-13 | Sitagliptin tannate complex |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112016023839A2 BR112016023839A2 (pt) | 2017-08-15 |
BR112016023839A8 true BR112016023839A8 (pt) | 2023-04-11 |
Family
ID=54324454
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112016023839A BR112016023839A8 (pt) | 2014-04-17 | 2015-04-13 | Complexo de tanato de sitagliptina, composição farmacêutica, intermediário farmacêutico, forma de dosagem oral, e, uso de um complexo de tanato de sitagliptina |
Country Status (12)
Country | Link |
---|---|
US (1) | US9833463B2 (pt) |
EP (1) | EP3131631B1 (pt) |
JP (1) | JP6523328B2 (pt) |
KR (1) | KR102351813B1 (pt) |
CN (1) | CN106456998B (pt) |
AU (1) | AU2015247921B2 (pt) |
BR (1) | BR112016023839A8 (pt) |
CA (1) | CA2945681A1 (pt) |
ES (1) | ES2932383T3 (pt) |
MX (1) | MX2016013588A (pt) |
RU (1) | RU2696588C2 (pt) |
WO (1) | WO2015160678A1 (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201818969A (zh) * | 2016-10-19 | 2018-06-01 | 日商帝化製藥股份有限公司 | 在生體內之藥物溶出控制用組成物 |
US11096890B2 (en) | 2017-09-29 | 2021-08-24 | Merck Sharp & Dohme Corp. | Chewable dosage forms containing sitagliptin and metformin |
DE112020006996T5 (de) | 2020-03-30 | 2023-01-12 | Mitsubishi Electric Corporation | Fahrstuhl |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997028149A1 (en) | 1996-02-02 | 1997-08-07 | Merck & Co., Inc. | Method for raising hdl cholesterol levels |
US5663415A (en) | 1996-06-28 | 1997-09-02 | Jame Fine Chemicals, Inc. | Process for preparing antihistamine tannates |
AR008789A1 (es) | 1996-07-31 | 2000-02-23 | Bayer Corp | Piridinas y bifenilos substituidos |
JP2003514508A (ja) | 1997-07-01 | 2003-04-15 | ノボ ノルディスク アクティーゼルスカブ | グルカゴン拮抗剤/逆作用剤 |
US6613942B1 (en) | 1997-07-01 | 2003-09-02 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
WO2000042026A1 (en) | 1999-01-15 | 2000-07-20 | Novo Nordisk A/S | Non-peptide glp-1 agonists |
ATE307798T1 (de) | 1999-05-17 | 2005-11-15 | Novo Nordisk As | Glucagon antagonisten/inverse agonisten |
RU2269354C2 (ru) | 1999-09-28 | 2006-02-10 | Байер Корпорейшн | Агонисты рецептора-3(r3) пептида-активатора гипофизарной аденилатциклазы(расар) и способы их фармакологического применения |
EP2206709A3 (en) | 2001-06-11 | 2011-06-29 | Virochem Pharma Inc. | Thiophene derivatives as antiviral agents for flavivirus infection |
UA74912C2 (en) * | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
US20030083354A1 (en) | 2001-10-26 | 2003-05-01 | Pediamed Pharmaceuticals, Inc. | Phenylephrine tannate and pyrilamine tannate salts in pharmaceutical compositions |
US6670370B1 (en) | 2001-12-14 | 2003-12-30 | Jame Fine Chemicals, Inc. | Dextromethorphan tannate |
US20030114535A1 (en) | 2001-12-14 | 2003-06-19 | Jame Fine Chemicals, Inc. | Dextrochlorpheniramine tannate |
JO2625B1 (en) | 2003-06-24 | 2011-11-01 | ميرك شارب اند دوم كوربوريشن | Phosphoric acid salts of dipeptidyl betidase inhibitor 4 |
AU2004268024B2 (en) | 2003-09-02 | 2007-07-12 | Merck Sharp & Dohme Llc | Novel crystalline forms of a phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
WO2005030127A2 (en) | 2003-09-23 | 2005-04-07 | Merck & Co., Inc. | Novel crystalline form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor |
WO2005072530A1 (en) | 2004-01-16 | 2005-08-11 | Merck & Co., Inc. | Novel crystalline salts of a dipeptidyl peptidase-iv inhibitor |
US20050202050A1 (en) * | 2004-03-12 | 2005-09-15 | Kiel Jeffrey S. | Single tank process for preparing tannate liquid and semi-solid dosage forms |
US7612072B2 (en) | 2004-09-15 | 2009-11-03 | Merck & Co., Inc. | Amorphous form of a phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
US20060270722A1 (en) * | 2005-05-31 | 2006-11-30 | Thornberry Nancy A | Combination of a dipeptidyl peptidase-IV inhibitor and a dual PPAR agonist for the treatment of diabetes and obesity |
US20090221592A1 (en) * | 2005-07-25 | 2009-09-03 | Ellison Martha E | Dodecylsulfate Salt Of A Dipeptidyl Peptidase-Iv Inhibitor |
WO2007050485A2 (en) * | 2005-10-25 | 2007-05-03 | Merck & Co., Inc. | Combination of a dipeptidyl peptidase-4 inhibitor and an anti-hypertensive agent for the treatment of diabetes and hypertension |
ES2420124T3 (es) * | 2006-12-14 | 2013-08-22 | Teva Pharmaceutical Industries Ltd. | Sal de tanato de rasagilina |
JP2011506442A (ja) | 2007-12-11 | 2011-03-03 | コンジュケム バイオテクノロジーズ インコーポレイテッド | インスリン分泌性ペプチド結合体の製剤 |
US8003672B2 (en) * | 2008-04-21 | 2011-08-23 | Merck Sharp & Dohme Corp. | CB-1 receptor modulator formulations |
EP2218721A1 (en) * | 2009-02-11 | 2010-08-18 | LEK Pharmaceuticals d.d. | Novel salts of sitagliptin |
US9211263B2 (en) | 2012-01-06 | 2015-12-15 | Elcelyx Therapeutics, Inc. | Compositions and methods of treating metabolic disorders |
-
2015
- 2015-04-13 WO PCT/US2015/025504 patent/WO2015160678A1/en active Application Filing
- 2015-04-13 KR KR1020167028345A patent/KR102351813B1/ko active IP Right Grant
- 2015-04-13 BR BR112016023839A patent/BR112016023839A8/pt not_active Application Discontinuation
- 2015-04-13 JP JP2016562508A patent/JP6523328B2/ja active Active
- 2015-04-13 RU RU2016144695A patent/RU2696588C2/ru active
- 2015-04-13 EP EP15780045.9A patent/EP3131631B1/en active Active
- 2015-04-13 CA CA2945681A patent/CA2945681A1/en not_active Abandoned
- 2015-04-13 CN CN201580020211.4A patent/CN106456998B/zh active Active
- 2015-04-13 US US15/302,211 patent/US9833463B2/en active Active
- 2015-04-13 ES ES15780045T patent/ES2932383T3/es active Active
- 2015-04-13 MX MX2016013588A patent/MX2016013588A/es active IP Right Grant
- 2015-04-13 AU AU2015247921A patent/AU2015247921B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
BR112016023839A2 (pt) | 2017-08-15 |
WO2015160678A1 (en) | 2015-10-22 |
JP2017511350A (ja) | 2017-04-20 |
CN106456998B (zh) | 2020-07-28 |
RU2696588C2 (ru) | 2019-08-05 |
MX2016013588A (es) | 2017-01-26 |
EP3131631B1 (en) | 2022-11-16 |
EP3131631A1 (en) | 2017-02-22 |
KR102351813B1 (ko) | 2022-01-18 |
KR20160145008A (ko) | 2016-12-19 |
AU2015247921B2 (en) | 2019-07-11 |
ES2932383T3 (es) | 2023-01-18 |
US20170042922A1 (en) | 2017-02-16 |
AU2015247921A1 (en) | 2016-10-13 |
RU2016144695A (ru) | 2018-05-21 |
CN106456998A (zh) | 2017-02-22 |
US9833463B2 (en) | 2017-12-05 |
JP6523328B2 (ja) | 2019-05-29 |
RU2016144695A3 (pt) | 2018-10-11 |
EP3131631A4 (en) | 2017-11-29 |
CA2945681A1 (en) | 2015-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SV2018005610A (es) | Derivados de oxopiridina sustituidos | |
CO2017005784A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
GT201700033A (es) | Anticuerpos anti tigit | |
BR112016025427A2 (pt) | processos de preparação de um inibidor de jak1 e formas do mesmo | |
CL2014000543A1 (es) | Compuestos derivados de imidazopiridazinas sustituidas con amino, inhibidores de la quinasa ,mknk2; metodo de preparacion; compuestos intermediarios y su uso; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratamiento del cancer. | |
CL2017001661A1 (es) | Compuestos biciclicos fusionados para el tratamiento de una enfermedad. | |
ECSP14013325A (es) | Piridopirazinas anticancerigenas via la inhibicion de cinasas del receptor del factor de crecimiento de fibroblasto (fgfr) | |
UY35916A (es) | Compuestos tricíclicos como agentes antineoplásicos inhibidores del bromodominio | |
CL2013003372A1 (es) | Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes. | |
GT200900230A (es) | 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso | |
IN2014CH00247A (pt) | ||
EA201691481A1 (ru) | ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ | |
GT201500235A (es) | Estra -1,3,5 (10) , 16- tetraeno -3-carboxamidas para la inhibicion de la 17b-hidroxiesteroide deshidrogenasa (akr1c3) | |
DK3170005T3 (da) | Fremgangsmåde til forudsigelse af resultatet af en behandling med aflibercept hos en patient, der mistænkes for at lide af cancer | |
CL2013002908A1 (es) | Uso de compuestos derivados de bencimidazol-4-carboxamida para el tratamiento profilactico de la neuropatia periferica inducida por quimioterapia . | |
UY36938A (es) | Nuevos compuestos macrocíclicos modificados | |
CO2017005566A2 (es) | Péptidos cíclicos derivados de cd44v6 para el tratamiento de enfermedades relacionadas con cánceres y angiogénesis | |
EA201790982A1 (ru) | Синтез копанлисиба и его дигидрохлорида | |
BR112017009012A2 (pt) | derivados de anel benzo de seis membros como inibidor de dpp-4 e seu uso | |
EA201400623A1 (ru) | Новые 2h-индазолы в качестве антагонистов рецептора ep | |
CL2016002839A1 (es) | Derivados de carboxamida | |
UY36923A (es) | Nuevos compuestos macrocíclicos de sulfondiimina | |
EP3223809A4 (en) | Amino acid compositions for the treatment of symptoms of disease | |
BR112017002852A2 (pt) | compostos de azetidiniloxifenilpirrolidina | |
MX2020009966A (es) | Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B07B | Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B154 | Notification of filing of divisional application [chapter 15.50 patent gazette] |
Free format text: O PEDIDO FOI DIVIDIDO NO BR122023000637-2 PROTOCOLO 870230003440 EM 12/01/2023 16:35. |
|
B25A | Requested transfer of rights approved |
Owner name: MERCK SHARP AND DOHME LLC (US) |
|
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B12B | Appeal against refusal [chapter 12.2 patent gazette] |